News

Ultragenyx noted that the fourth cohort would use a “moderately increased” dose and an optimized immunodulation regimen.

Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen, discussed OCU400, the company’s gene-agnostic gene therapy for IRDs.

As cell therapy investigations mature in the field of AD, some programs show promising signs of efficacy.

The vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization discussed the Autoimmunity Cell Therapy Network.

NEXICART-2 has moved on to its expansion cohort after completing dosing of patients in its initial cohort.

Review top news and interview highlights from the week ending October 4, 2024.

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.

Estrella noted that the patient had been diagnosed with follicular lymphoma grade 3A with high-risk 3B symptoms.

Daniel Hart, PhD, the senior director and head of technology development at Epic Bio, discussed potential applications of the new technology.

CSF analyses from 7 patients treated in the study showed reductions of more than 80% in NAA levels from baseline.

Anixa noted that it had previously obtained clearance of a single-patient investigational new drug application to redose a patient in the trial.

The data, from the CARTITUDE-4 clinical trial, compared outcomes to patients treated with standard of care options.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

The chief scientific officer and head of research, development, and Medical at Ocugen, also discussed future plans for the gene therapy, which is now in a phase 3 study.

The company pointed out that today, September 30, is LGMD Awareness Day.

In observance of Rare Cancer Day, held annually on September 30, catch up on the past few months’ news related to gene and cell therapies in development for these indications.

In observance of World Heart Day, held annually on September 29, we took a look back at the past year's news in cell/gene therapy for cardiovascular disease.

John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia, discussed several still-investigational drugs and therapies for DMD.

Review top news and interview highlights from the week ending September 27, 2024.

Enrollment difficulties were cited as the reason for discontinuing recruitment activities for KarMMa-9.

The approvals are indicated for patients 12 years and older.

Notably, today, September 26, is annually observed as Mesothelioma Awareness Day by the patient and clinician communities.

The chief scientific officer and head of research, development, and Medical at Ocugen, discussed OCU400, the company’s gene-agnostic gene therapy for IRDs.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia, discussed the complicated choice doctors, patients, and families now face with a wide range of treatment options available.

In lymph node biopsies from patients treated in the study, a mean exposure of 236,701 CAR T-cells per million across all dose levels was observed.

There were no SUSARS and no endophthalmitis observed among 29 patients treated in the study.

Kiromic anticipates that Deltacel-01's expansion portion, which is expected to include around 9 new patients, will begin screening patients before the end of September.